Drug Profile
E 2814
Alternative Names: E-2814Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Eisai Co Ltd; University College London
- Developer Eisai Co Ltd
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Alzheimer's disease
Most Recent Events
- 16 Jul 2023 Adverse event, pharmacokinetics, pharmacodynamics, immunogenicity data from a phase I trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2023 (AAIC-2023)
- 16 Jul 2023 Pooled analysis adverse event, pharmacokinetics and pharmacodynamics, from a phase-I and phase-I/II trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2023)
- 09 Mar 2023 Eisai completes a first-in-human phase I trial in Alzheimer's disease (In volunteers) in USA (IV) (NCT04231513)